George Kemble ’83 has been appointed to the Scientific Advisory Board of Mymetics, a leader in the development of mucosal and virosomal-based vaccines for infectious diseases. Dr. Kemble is currently the CSO at 3-V Biosciences, a biotech company with a unique approach to antiviral drug discovery and development. He is a leading authority on vaccine development and in particular the development of vaccines for RSV. Dr. Kemble was responsible for the research and development of multiple products, including the successful launch of FluMist.

22 Aug 2012